We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.34% | 1.475 | 1.45 | 1.50 | 1.475 | 1.475 | 1.475 | 636,264 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.28 | 11.4M |
TIDMSTX
RNS Number : 2986C
Shield Therapeutics PLC
18 June 2021
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Directorate Change
London, UK, 18 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), announces that further to the announcement issued on 28 May 2021, Greg Madison will join the Board with immediate effect and is fulfilling the role of the Group's Chief Executive Officer.
Shield also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies.
Full name: Gregory Paul Madison
Age: 53 years
Current directorships/partnerships:
-- American Kidney Fund, Board of Trustees
Previous directorships/partnerships held in the past 5 years:
-- Melt Pharmaceuticals, Inc. -- Keryx Biopharmaceuticals, Inc. -- Keryx Biopharma UK Ltd.
Mr Madison currently does not hold any ordinary shares in Shield.
There are no other disclosures required in connection with the appointment of Mr Madison under Schedule Two(g) of the Aim Rules for Companies.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com Greg Madison, CEO +44 (0) 191 511 8500 Lucy Huntington-Bailey Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Christopher Golden +44 (0)20 7418 8900 Joint Broker finnCap Ltd Geoff Nash/Alice Lane/George Dollemore +44 (0)20 7220 0500 Financial PR & IR Advisor Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com Paul McManus/Lianne Cawthorne
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer(R) in the US during 2021 through a highly experienced sales and marketing team. Feraccru(R) is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAMZGMVKNLGMZM
(END) Dow Jones Newswires
June 18, 2021 02:00 ET (06:00 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions